These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 32574106)

  • 1. Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?
    Hussain N; Naeem M; Pinato DJ
    Hum Vaccin Immunother; 2021 Jan; 17(1):55-61. PubMed ID: 32574106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
    Buti S; Bersanelli M; Perrone F; Tiseo M; Tucci M; Adamo V; Stucci LS; Russo A; Tanda ET; Spagnolo F; Rastelli F; Pergolesi F; Santini D; Russano M; Anesi C; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Occhipinti MA; Ferrari M; Vitale MG; Nicolardi L; Chiari R; Rijavec E; Nigro O; Tuzi A; De Tursi M; Di Marino P; Conforti F; Queirolo P; Bracarda S; Macrini S; Gori S; Zoratto F; Veltri E; Di Cocco B; Mallardo D; Vitale MG; Santoni M; Patruno L; Porzio G; Ficorella C; Pinato DJ; Ascierto PA; Cortellini A
    Eur J Cancer; 2021 Jan; 142():18-28. PubMed ID: 33212418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors.
    Gandhi S; Pandey M; Ammannagari N; Wang C; Bucsek MJ; Hamad L; Repasky E; Ernstoff MS
    Immunotherapy; 2020 Feb; 12(2):141-149. PubMed ID: 32064978
    [No Abstract]   [Full Text] [Related]  

  • 4. Managing side effects of immune checkpoint inhibitors in breast cancer.
    Criscitiello C; Corti C; Pravettoni G; Curigliano G
    Crit Rev Oncol Hematol; 2021 Jun; 162():103354. PubMed ID: 34029683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer.
    Iglesias-Santamaría A
    Clin Transl Oncol; 2020 Sep; 22(9):1481-1490. PubMed ID: 31919759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing toxicities associated with immune checkpoint inhibitors.
    Park JJ; Arafath S; Kumar ST; Sharma R; Dixit D
    JAAPA; 2021 Jun; 34(6):32-39. PubMed ID: 34031312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients.
    Li Y; Wang Y; Li N; Liang X; Zhang S; Fan Q; Yin X; Zhuang Z; Liu Y; Zhang J; Kou X; Zhong H; Xu B; Huang J
    Chin Med J (Engl); 2022 Apr; 135(8):988-990. PubMed ID: 35730374
    [No Abstract]   [Full Text] [Related]  

  • 8. Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects.
    Chen X; Zhang W; Yang W; Zhou M; Liu F
    Aging (Albany NY); 2022 Jan; 14(2):1048-1064. PubMed ID: 35037899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications.
    Spakowicz D; Hoyd R; Muniak M; Husain M; Bassett JS; Wang L; Tinoco G; Patel SH; Burkart J; Miah A; Li M; Johns A; Grogan M; Carbone DP; Verschraegen CF; Kendra KL; Otterson GA; Li L; Presley CJ; Owen DH
    BMC Cancer; 2020 May; 20(1):383. PubMed ID: 32375706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors.
    Williams KJ; Grauer DW; Henry DW; Rockey ML
    J Oncol Pharm Pract; 2019 Apr; 25(3):544-550. PubMed ID: 29224458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the "inflamed tumor" to the "inflamed patient".
    Bersanelli M; Cortellini A; Buti S
    Hum Vaccin Immunother; 2021 Jul; 17(7):1930-1934. PubMed ID: 33427023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ["Immune checkpoint inhibitors in oncology"].
    Daëron M; Vivier É
    Rev Prat; 2021 Apr; 71(4):374-379. PubMed ID: 34161001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tracking Research Progress in the Modulatory Role of Gut Microbiome in Immune Checkpoint Inhibitors Applied in Cancer Treatment].
    Wu MR; Tang MY; Zheng BH; Zhou ST
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Sep; 52(5):735-739. PubMed ID: 34622585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario.
    Rossi G; Pezzuto A; Sini C; Tuzi A; Citarella F; McCusker MG; Nigro O; Tanda E; Russo A
    Crit Rev Oncol Hematol; 2019 Oct; 142():26-34. PubMed ID: 31352168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].
    Tang H; Guan M; Sun Z; Bai CM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Dec; 42(6):825-830. PubMed ID: 33423733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances on immune-related adverse events associated with immune checkpoint inhibitors.
    Fan Y; Geng Y; Shen L; Zhang Z
    Front Med; 2021 Feb; 15(1):33-42. PubMed ID: 32779094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Setting the scene - a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy.
    Bermudez MV; Papa S
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii1-vii6. PubMed ID: 31816083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
    Nagai H; Muto M
    Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
    Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J
    Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
    Weinmann SC; Pisetsky DS
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.